AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
RM-055
3 people · 3 posts
Heat trend for this story
Heat now 1·Peak in the comparable set 2 (Apr 22 13:00)·Change over 24h in the comparable set –·Participants now 2
Participants counted2
Heat over time
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
Records
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
- zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
Floor
x.com@Score6060 x.com@Score6060 x.com@Score6060